Therefore, it should be clarified whether targeting ERO1-α in tumor cells results in augmentation of T-cell-mediated tumor cell killing in vitro as well as in an immunocompetent mouse model of breast cancer. This evidence concerns the gene ERO1A and breast carcinoma.